SCHEMBL28058588

SCHEMBL28058588

O=[N+]([O-])c1cnc2ccccc2c1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.51
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 1/20 0.44
GPR3 P46089 1/20 0.44
NCOA1 Q15788 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 1/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPK1 P28482 1/20 0.42
ABCG2 Q9UNQ0 2/20 0.40
PIM1 P11309 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8561101 0.81 POLB (0.53) POLBMEN1KMT2AKDM4EGPR3
SCHEMBL202880 0.79 POLB (0.51) POLBMEN1KMT2AKDM4ENCOA1
SCHEMBL1033969 0.79 POLB (0.51) POLBMEN1KMT2AKDM4ENCOA1
SCHEMBL202663 0.79 POLB (0.51) POLBMEN1KMT2AKDM4ENCOA1
SCHEMBL4727431 0.79 POLB (0.51) POLBMEN1KMT2ANCOA1NCOA3
SCHEMBL29381779 0.79 POLB (0.51) POLBMEN1KMT2AKDM4ENCOA1
SCHEMBL15824026 0.79 POLB (0.51) POLBMEN1KMT2AKDM4EGPR3
SCHEMBL8570782 0.79 POLB (0.51) POLBMEN1KMT2AKDM4EGPR3
SCHEMBL8562573 0.79 POLB (0.47) POLBMEN1KMT2ANCOA1NCOA3
SCHEMBL31197366 0.78 POLB (0.50) POLBMEN1KMT2AKDM4ENCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106255692-A Imidazo [4,5-c ] quinolin-2-one compounds and their use in treating cancer 阿斯利康(瑞典)有限公司 2016-12-21 CN disclosed
CN-105473588-A Compounds and compositions as inhibitors of MEK NOVARTIS AG 2016-04-06 CN disclosed